Table of Contents  Please read below for news-worthy NewsTips and other information including:

-- MedIntelliBase Introduction >> --On Line, On-Time, On Demand--

-- New Drug for the Treatment of Endovascular Disease

-- Clinical Study in Endovascular Therapeutics

-- Clinical Study in Cardiovascular Therapeutics

-- More Information Available at www.MedIntelliBase.com!

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

A Happy Holidays and New Year to you from our team at The Next Phase Publishing! We hope 2006 will be very successful for you and your organization.

This December issue of MedIntelliBase™ (MIB) NewsTips provides you with the late breaking NewsTips from our Cardiovascular and Endovascular Therapeutics MarketTracks.

To learn more about these and many more trials and therapies please let me know - we just released our Endovascular Therapeutics MIB databases for subscription and our Cardiovascular MarketTrack was again updated in mid-December.

At the request of a few of our clients we also have extended our year- end offer through January 31 to allow you ample budget review time. To introduce you to our innovative products my team and I are offering you a 40% discount on all MedIntelliBase MarketTracks. Just visit our webpage, http://www.MedIntelliBase.com/products.html, to learn more about each of our products, and call me to place this special order. I hope you will take advantage of our limited-time offer.

As always, our MedIntelliBase Team - Tyler Mittleider, Jordan Zornes, and I – think you will find great value in this information...and our extended offer. Use them in good health!

May 2006 be a great year for you!

Vicky Hunsicker Sanko
President
The Next Phase® Publishing, Inc.
Phone - 425/869-8724
Fax - 425/869-9397

MedIntelliBase Introduction >> --On Line, On-Time, On Demand-- ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

If you are tired of outdated, canned market research reports or databases that do not offer the intelligent insights and analysis you need...then MedIntelliBase is for you. Each month our MIB NewsTips e-newsletters will provide you with a glimpse into our up-to-date MedIntelliBase MarketTracks - capturing the most recent market, clinical research and technology intelligence. Our first MarketTracks - the Interventional Medicine Series - cover Cardiovascular, Endovascular, Carotid Artery & Stroke, and Neurovascular Therapeutics.

Take a moment to learn even more about this exciting new way to access up-to-date information and intelligence>>

Visit our webpage at www.MedIntelliBase.com...

New Drug for the Treatment of Endovascular Disease ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

NM-702 is a new antiplatelet agent in development for patients with Peripheral Artery Disease (PAD). It is currently being evaluated in a Phase II clinical study (see below) for the treatment of intermittent claudication. Nissan Chemical Industries and Taisho Pharmaceutical Co., Ltd., both operating in Japan, are collaborating on the development of this new drug. NM-702 is described as a powerful inhibitor of phosphodiesterase (PDE) III & V and thromboxane A2 (TXA2) synthesis.

Clinical Study in Endovascular Therapeutics ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

The US-based "Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication" study is currently evaluating NM-702 in patients 50 years or older with stable, symptomatic, intermittent claudication caused by lower extremity atherosclerotic disease. This randomized, double- blind, placebo-controlled study is designed to evaluate the drug's safety and efficacy in 390 patients when taken twice daily (4 mg and/or 8 mg BID) for 24 weeks to determine if peak walking time is improved. Data from this study should be available following its expected completion in April 2006.

Clinical Study in Cardiovascular Therapeutics ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

The SPIRIT III trial - "A Clinical Evaluation of the XIENCE(TM) V Everolimus Eluting Coronary Stent System (CSS) in the Treatment of Subjects with De Novo Native Coronary Artery Lesions" - is currently enrolling an expected 1,380 patients to evaluate the XIENCE V everolimus-eluting coronary artery stent system from Guidant Corporation. The objective of this study is to demonstrate the safety and efficacy of the XIENCE V stent system compared with Boston Scientific's TAXUS Express2 paclitaxel-eluting coronary stent system in a large scale pivotal study. Patients will be randomized in two US arms, non- randomized in three US arms, and the study includes a non-randomized arm in Japan. The primary endpoint is in-segment late lumen loss (LLL) at 240 days, and a major secondary endpoint is ischemia-driven target vessel failure (TVF) at 270 days.

More Information Available at www.MedIntelliBase.com! ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

You can find more information about the summaries above and many more technologies and clinical studies in MedIntelliBase >> visit our website at www.MedIntelliBase.com

We will be pleased to help you access the critical intelligence you need to make informed product development and business investment decisions.

Contact us if you need more information...

You can find other related services at our sister division's website at The Next Phase Consultancy's Home Page.

FYI:

1. MedIntelliBase NewsTips is free and you are welcome to continue receiving it as long as you wish. If at any time you wish to cancel just click the Safe Unsubscribe link below.
2. We will not share your name and e-mail address with anyone.
3. Feel free to share or reproduce the information in this MedIntelliBase NewsTips e-newsletter (in whole or part) as long as proper mention and copyright notice is given to MedIntelliBase and The Next Phase Publishing, Inc.
4. If you are not the original recipient of this newsletter and would like to receive future issues, just click the Forward link below or drop me a line.

Editor: Vicky Hunsicker Sanko
The Next Phase Publishing, Inc.
Phone - 425/869-8724
Fax - 425/869-9397